drugset
drugset / Trial / NCT02555124

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

NCT02555124 ↗

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety of JNJ-42847922 following single oral administration.

Timeline

Start
2015-09-12
Primary completion
2015-10-31
Completion
2015-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule 5 mg Oral
Subject Seltorexant Small molecule 20 mg Oral
Subject Seltorexant Small molecule 40 mg Oral

Indications

No indication recorded.